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upon standardized and sustained data collection routines. 
The described institutional contact indicator revealed to be 
a useful tool in the context of PDU/IDU prevalence estima-
tions and thus contributes to enhancing evidence-based 
drug policy planning.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 There is a series of reasons why it may be important to 
know the size of a population showing drug use or misuse 
in a given area, such as gathering knowledge on its com-
position and its distribution within the general popula-
tion and the willingness to affect its prevalence.
 Different techniques exist to estimate the extent of 
drug use. Also, researchers and stakeholders want these 
techniques to be valid, reliable, reproducible and cost-ef-
fective at best. Summarily, direct and indirect methods 
may be applied. Indirect estimation techniques tend to 
build upon existing data and their mutual relationship in 
order to estimate the number of non-observed cases in 
a given population. The latter include capture-recap-
ture techniques  [1–8] , benchmark-multiplier methods  [1, 
9–11] , the truncated Poisson method  [1, 12, 13] , and the 
multivariate indicator method  [14–19] . However, none of 
currently known methods is considered to be the gold 
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 Abstract 
 Background: To estimate the prevalence of problem drug 
use (PDU) and injecting drug use (IDU) in Luxembourg and 
analyze trends between 1997 and 2009. To assess the feasi-
bility of prevalence estimations based on drug use surveil-
lance systems.  Methods: Serial multi-method PDU/IDU prev-
alence estimations based upon capture-recapture, Poisson 
regression, multiplier and back-calculation methods. Com-
parative analysis of methods and assessment of their robust-
ness to variations of external factors.  Results: National PDU 
and IDU prevalence rates were estimated at 6.16/1,000
(95% CI 4.62/1,000 to 7.81/1,000) and 5.68/1,000 (95% CI 
4.53/1,000 to 6.85/1,000) inhabitants aged 15–64 years, re-
spectively. Absolute prevalence and prevalence rates of PDU 
increased between 1997 and 2000 and declined from 2003 
onwards, whereas IDU absolute prevalence and prevalence 
rates witnessed an increasing trend between 1997 and 2007. 
 Conclusions: Drug use surveillance systems can be valuable 
instruments for the estimation and trend analysis of drug 
misuse prevalence given multiple methods are applied that 
rely on serial and representative data from different sources 
and different settings, control multiple counts and build 
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standard since they all rely on a series of assumptions and 
limitations  [20] .
 A first reason for this refers to data sources and data 
settings. Methods to estimate drug prevalence may rely 
on various data such as provided by routine drug use sur-
veillance or monitoring systems, by cross-sectional stud-
ies or by more or less representative surveys. In case drug 
use reporting systems do provide data for prevalence es-
timations, one has to bear in mind that these are by defi-
nition selective as they generally gather information on 
drug use from services in contact with drug users  [21] . As 
such, they merely include cases that come to the attention 
of those institutions, thus representing only a variable 
share of the target population.
 Additionally, in the context of drug prevalence estima-
tions, drug use surveillance systems predominantly rely-
ing on drug treatment data, also present serious limita-
tions  [22] such as possible delays between onset of drug 
use and first treatment demand  [23] , variable availability 
and accessibility of treatment facilities, exclusion of out-
of-treatment subpopulations and possible lack of control 
mechanisms to avoid multiple counting  [24] .
 Previous research does suggest favoring a multisource 
approach (e.g. in- and out-of-treatment settings)  [22, 23] , 
multi-method study designs  [6, 20, 25, 26] and cross-
checking indirect trend indicators  [23, 27] . This said, 
there appears to be a lack of a formal and appropriate 
framework to combine various instruments, methods 
and data to optimize the validity of drug prevalence esti-
mates other than simply look for their concordance and 
to assess the extent to which they converge to a plausible 
estimate  [26, 28] .
 In the light of these constraints, the Luxembourg 
drug use surveillance system (RELIS), established in 
1995, was built upon the methodological assumption 
that data exclusively from drug treatment settings may 
not provide an accurate picture of problem drug use 
(PDU) as these notably exclude out-of-treatment users 
whose drug use has generated conflicts with law enforce-
ment only. Hence, to approach the genuine heterogeneity 
of the drug misuse phenomenon, RELIS routinely com-
piles data from all existing specialized in- and out-of-
treatment sources, in- and outpatient service sources
(n = 7), low threshold agencies (n = 2), psychiatric depart-
ments of general hospitals (n = 5), substitution treatment 
program (n = 1), prison (n = 1) and law enforcement reg-
isters (n = 2). Also, RELIS relies on the ‘institutional con-
tact indicator’ as an alternative to the more commonly 
used ‘treatment demand indicator’  [23] and does not pri-
marily apply case definitions such as injecting drug us-
ers, heroin or opiate users. Even though RELIS software 
does allow to extract data on these subgroups, it targets 
‘problem drug use’ defined as follows: ‘Injecting drug use 
or long duration/regular use of opioids, cocaine and/or 
amphetamines’.
 This definition leads to a second important consider-
ation, namely the use of data gathered through drug use 
surveillance systems. The national surveillance data on 
drug misuse are intended to serve policy-making, action 
planning and resources allocation, building upon the 
principle that ‘Effective drug policy should be based on a 
systematic and comprehensive assessment of the nature 
extent and distribution of drug use within a community’ 
 [29] . The first aim of drug use surveillance and preva-
lence studies should be to reach benefits in terms of care 
for the target population. This target population does not 
exclusively consist of heroin addicts or drug users in 
treatment for instance. It is composed of persons encoun-
tering diverse problems stemming from their drug use in 
the first place and potentially also causing damage to the 
community. Therefore, the case definition of PDU is pre-
ferred to more restrictive ones because it arguably pro-
vides a more accurate picture of the extent of the problem 
and its correlates.
 The particular question addressed in this paper is to 
know how to conceive a reliable, construct valid and cost-
effective battery of tools and methods within the frame-
work of a national drug use surveillance routine to assess 
the prevalence of PDU. In other words, what are possible 
ways to arrange the patchwork of mostly scattered data 
on the extent and the pattern of PDU into a structured, 
reliable and valid body of evidence? There is presumably 
no single answer to this question, but it should be possible 
to investigate relationships between different instru-
ments and methods as well as their respective strengths 
and weaknesses to assess the robustness of a national 
drug prevalence estimation procedure and thus the ac-
curacy of its outcome.
 Methods 
 Serial estimates of problem drug users were obtained by apply-
ing the following methods: two-, three- and four-source capture-
recapture (CR) based on data from all existing national facilities 
for detoxification treatment, outpatient substitution treatment, 
inpatient drug therapy, as well as data on drug users yearly in-
dexed by law enforcement agencies; truncated Poisson regression 
model (tPm) associated to Zelterman’s and Chao’s estimators on 
RELIS contact frequencies and four multiplier computations re-
spectively combining datasets on first drug law offenders and the 
rate of acute drug death victims known by law enforcement agen-
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cies (M1) 1 , on drug use law offenders and the proportion of prob-
lem drug users in contact with police (M2), on drug-related death 
cases and drug-related mortality rates (M3), and on drug treat-
ment admissions and in-treatment rates (M4). CR on two and 
three sources, tPm, M1 and M2 were performed in all serial stud-
ies from 1999 to 2009 respectively on the same sources. Due to the 
restructuration of the main national psychiatric hospital (CHNP), 
detoxification treatment has been decentralized within four re-
gional hospitals running psychiatric services, which were includ-
ed in CR models in 2009 instead of the CHNP. 
 Estimates of injecting drug users were obtained by multiply-
ing PDU estimates by IDU rates in the national PDU population 
as provided by RELIS on a yearly basis (P[PDU/IDU]). In order to 
consolidate the final estimation outcome, a back-calculation 
method based on HIV data was also applied. The number of HIV-
infected injecting drug users has been used as numerator and the 
proportion of HIV infections among injecting drug users as de-
nominator to estimate the total number of injecting drug users 
(M[IDU/HIV]). Where appropriate, 95% CI and mid-point esti-
mates were calculated. Lower and upper bounds of results, as pro-
vided by applied methods, were used to set estimation margins. 
 Data were provided by the national RELIS surveillance sys-
tem, maintained by the Luxembourg focal point of the EMCDDA. 
Drug users indexed by RELIS are digitally anonymized by means 
of an encryption algorithm approved by the National Commis-
sion on Data Protection. The thus obtained individual RELIS 
code allows respondents’ recognition within and between sources 
and to avoiding multiple counts.
 Statistical analysis was carried out with SPSS 13.0/19.0 soft-
ware and GLIM 4 update 9 (for 2003 and 2007 CR computations 
only). log-linear analysis was used for three- and four-source CR 
computations. CR models were compared using the log likelihood 
ratio (G 2 ), the Aikaike’s information criterion (AIC)  [30] and the 
bayesian information criterion (BIC)  [31] . The simplest models 
with the lowest AIC and BIC scores were retained in case any more 
complex model with a significantly lower G 2 was observed.
 Results 
 Table 1 shows estimates of problem and injecting drug 
users as calculated by applied methods. Results provided 
by different methods show reasonable inter-estimate 
margins per year, varying from 400 to 743 persons be-
tween 1997 and 2009, excluding estimates derived from 
the tPm Zelterman estimator. As a matter of fact, the Zel-
terman estimator provides the highest estimates for all 
years except for 2009, thus not reflecting, likewise the M2 
estimates, the serial prevalence trend line documented by 
all other methods. Capture-recapture methods on two, 
three and four sources, tPm and M1 provided the most 
consistent PDU estimates. tPm Chao’s estimator tend to 
bring up lower-bound estimates and M2 to provide high-
est serial estimates.
 Until 2003, serial IDU estimates provided by the 
P(PDU/IDU) method were higher than those derived 
from M(IDU/HIV), but observed differences are reason-
ably small, varying between 20 and 310 persons.
 Table 2 provides an overview of mean PDU and IDU 
prevalence estimates as calculated by different methods 
and sources, associated 95% CIs and prevalence rates per 
1,000 inhabitants in the total national population and in 
the population aged 15–64 years. 
 The latest serial estimate (2009 data) provided a mean 
prevalence of 2,070 (median 2,094) problem drug users at 
the national level (95% CI 1,553–2,623). In terms of prev-
alence rates, 4.19/1,000 and 6.16/1,000 inhabitants out of 
the general population and aged between 15 and 64 years 
respectively show PDU. The number of injecting drug us-
ers was estimated at 1,907 persons representing an IDU 
prevalence rate of 5.68/1,000 inhabitants aged between 15 
and 64 years.
 According to serial estimates performed between 1997 
and 2009 ( fig. 1 ), absolute prevalence and prevalence rates 
of PDU showed an increasing trend until 2000. After a 
brief stabilization phase, a downward trend, observed 
from 2003 onwards, was confirmed by most applied 
methods. Absolute prevalence of IDU, however, increased 
between 1997 and 2007, and so had the IDU prevalence 
rate in the national population aged 15–64. Data for 2009 
show a decrease in IDU prevalence that should, however, 
be interpreted only in the light of future serial data.
 Discussion 
 We conducted a serial, multi-method/multi-source 
prevalence study on problem and injecting drug users in 
Luxembourg, applying various estimation techniques 
based on data provided by the national drug use surveil-
lance system (RELIS). We then confronted serial esti-
mates, provided by comparable methodologies allowing 
to follow-up the evolution of national PDU and IDU prev-
alence over a period of 13 years between 1997 and 2009.
 Serial estimates suggest that even though the absolute 
number of problem drug users has not been increasing 
 1   Calculated for the average duration of drug dependence of the target 
population. Duration of dependence being a routine item of the RELIS 
surveillance protocol, 10 and 11 years were determined and applied for 
1999/2000/2009 and 2007 respectively. Data on first offenders and acute 
drug deaths have been extracted from the national registers on drug law 
offenders and on drug-related deaths. Toxicological evidence allowed to 
determine that all included overdose cases showed ante-mortem heroin 
and/or cocaine and/or amphetamines consume. Heroin use was detected 
in almost all cases. Three indexed victims, on transit and not residents of 
Luxembourg, were excluded. 
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for several years, the needs in terms of prevention, care 
and treatment have nonetheless changed to a large extent. 
The high and increasing rate of polydrug use in problem 
drug users (2007) and the increasing number of drug-
related death cases during the referred period  [32] tend to 
corroborate this statement. In other words, a seemingly 
decreasing number of drug users appear to have devel-
oped more hazardous and care-demanding consume pat-
tern. This is an important observation since it shows that 
prevalence data might allow to assess the size of a popula-
tion but not necessarily the extent of a problem and its 
correlates. 
 A detailed comparative analysis of single estimates re-
vealed that capture-recapture models are valuable tools 
for drug prevalence estimation and its methodological 
constraints have been thoroughly described in the litera-
ture  [1–8] . Accordingly, a fundamental application as-
sumption of CR requires the studied population to be 
closed; there should be no movement into or out of the 
population during the study period. Obviously, applied to 
problem drug users, this condition is unlikely to be fully 
met as some of them might die, relapse, quit or newly join 
the PDU population during the study. A capture-recap-
ture period limited to 1 year was therefore chosen to re-
duce potential bias introduced by the violation of the 
‘closed population assumption’. 
 A second important assumption regards homogeneity 
of the study population; each individual should have the 
same probability of being present in each source. The 
likelihood of being indexed, however, relies on individu-
al factors such as severity of drug dependence in associa-
tion with increased risk behavior, socioeconomic status 
 [33] , current treatment or incarceration status as well as 
on structural factors such as differences in availability or 
accessibility of existing treatment facilities.
 Since Luxembourg stands for a rather small territory 
and the PDU population is concentrated in two major cit-
ies where demand reduction and supply reduction offers 
and measures were comparable and stable between 1997 
and 2009, the impact of structural factors should be lim-
ited. On the other hand, easy and payment-free access to 
national treatment offers may result in increased treat-
Sourcesa/models Year Retained model Total
observed
Hidden population
(estimation)
Total
population
95% CI
PDU estimates – method: capture-recapture
CR 2 sources
P1999 & M1999 1999 / 700 1,375 2,075 1,587–2,563
P2000 & M2000 2000 / 636 1,980 2,616 1,801–3,431
P2003 & M2003 2003 / 574 1,816 2,390 1,966–2,814
P2007 & M2007 2007 / 536 1,837 2,373 1,479–3,266
P2009 & HO2009 2009 / 371 1,485 1,856 1,016–2,696
CR 3 (1) sources
H1999 & P1999 & M1999 1999 H1999 * P1999
H1999 * M1999
664 1,663 2,327 1,510–3,926
H2003 & P2003 & M2003 2003 H2003 * P2003 594 2,051 2,645 1,871–3,986
H2007 & P2007 & M2007 2007 H2007 * P2007 497 2,114 2,611 1,703–4,401
H2009 & P2009 & M2009 2009 P2009 * M2009 409 1,691 2,100 1,373–3,375
CR 3 (2) sources
P2000 & M2000 & T2000 2000 P2000 * T2000
T2000 * M2000
656 1,920 2,576 1,917–3,578
P2003 & M2003 & T2003 2003 Independence 505 2,043 2,548 1,773–3,911
P2007 & M2007 & T2007 2007 Independence 491 1,699 2,190 1,567–3,244
CR 4 sources
H2000& P2000 & T2000& M2000 2000 H1999 * P1999
H1999 * T1999
P2000 * T2000
T2000 * M2000
719 2,156 2,875 2,156–3,948
H2003& P2003 & T2003& M2003 2003 P2003 * H2003 
T2003 * H2003
629 1,827 2,456 1,825–3,466
H2007& P2007 & T2007& M2007 2007 P2007 * H2007 534 1,644 2,178 1,595–3,131
Table 1.  Estimates of absolute prevalence of PDU and IDU in Luxembourg, 1997–2009
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Table 1 (continued)
Estimator Year Total
observed
Hidden population
(estimation)
Total
population
95% CI
PDU estimates – method: truncated Poisson model (tPm) – Zelterman & Chao estimators (1 source)
Zelterman est. (Zn) 1999 744 2,133 2,877 2,659–3,133
2000 783 2,141 2,924 2,710–3,176
2003 3,206 2,880–3,537
2007 3,175 2,780–3,786
2009 779 1,308 2,087 1,809–2,467
Chao est. (Cn) 1999 744 1,333 2,077 1,912–2,290
2000 783 1,349 2,132 1,968–2,342
2003 2,332 2,105–2,621
2007 2,470 2,146–2,890
2009 779 944 1,723 1,496–2,022
Sources Year Total
Population
Estimation
margins
PDU estimates – method: benchmark multipliers
M1
Law enforcement data/drug-related death data 1999 2,350 2,209–2,483
2003 2,650 2,587–2,721
2007 2,515 2,347–2,681
2009 2,166 1,994–2,338
M2
Law enforcement data/law enforcement contact rate 1997 2,300 /
1999 2,624 /
2003 2,008 /
2007 2,220 /
2009 2,340 /
M3
Drug-related death data/DRD rate 1999 2,120 2,087–2,155
M4
Treatment data/in-treatment rate 1997 1,900 /
IDU estimates
Method: P(IDU/PDU) 1997 1,785 /
1999 1,828 /
2000 1,920 /
2003 1,755 /
2007 1,924 /
2009 1,524
Method: M(IDU/HIV) 1997 1,582 /
1999 1,686 /
2000 1,610 /
2003 1,735 /
2007 2,422 /
2009 2,301 /
a  CHNP (H) = clients registered by main national detoxification unit; Hospitals (HO) = all national hospitals providing detoxifica-
tion treatment; SPJ (P) = drug users indexed by national law enforcement agencies; CTM (T) = inpatient drug therapy clients nation-
wide; MP (M) = outpatient substitution treatment demanders indexed nationally by specialized agencies; PDU =  problem drug users; 
IDU = injecting drug users.
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ment rotation by patients. In order to assess the homoge-
neity of the target population, we performed a compari-
son of the sum of estimations applied to gender-stratified 
samples with the total estimation performed on non-
stratified samples. As the results obtained by both ap-
proaches were highly similar, homogeneity of the study 
population could be reasonably assumed.
 The homogeneity assumption appears to be related to 
an additional condition requiring that being present in 
one source should not affect the probability of being 
in another source. A positive dependence between two 
sources included in the CR model would result in an un-
derestimation of the total population, and vice versa. To 
reduce the potential impact of a violation of the mutual 
independence assumption, both supply and demand re-
duction sources were included in the CR models. Fur-
thermore, sources linked to each other by agreed, routine 
or systematic referral procedures were not combined for 
the same reason. Ultimately, it should be stressed that CR 
analysis including more than two sources accounts for 
potential dependences between selected sources in the se-
lection of best-fitted regression models.
 The truncated Poisson model (tPm) may be seen as a 
particular application of a CR model, based on a single 
data source. Also, a ‘drug use-related institutional con-
tact’ can be described as being a rare event, following a 
Poisson-shaped distribution  [34] . Matching observation-
al data with a Poisson distribution thus allows estimating 
the number of persons that have not been indexed in a 
given setting or database, hence representing the hidden 
Table 2.  Absolute prevalence and prevalence rates according to selected subgroups in Luxembourg, 1997–2009
1997 1999 2000 2003 2007 2009
General population
National population on 1st January 418,300 429,200 435,700 448,300 476,200 493,500
National population aged 15–64 years on 1st January 281,100 287,100 291,000 300,800 322,000 336,015
Problem drug users
PDU mean prevalence 2,100 2,350 2,625 2,530 2,470 2,070
Mean 95% CI 1,900-2,300 1,994–2,758 2,246–3,295 2,144–3,293 1,945–3,343 1,553–2,623
Total mean prevalence rate 5/1,000 5.48/1,000 6.02/1,000 5.64/1,000 5.19/1,000 4.19/1,000
Total mean prevalence rate (age 15–64) 7.47/1,000 8.19/1,000 9.02/1,000 8.41/1,000 7.67/1,000 6.16/1,000
Injecting drug users
IDU mean prevalence 1,656 1,757 1,765 1,745 2,173 1,907
Estimate margins 1,528–1,785 1,686–1,828 1,610–1,920 1,735–1,755 1,924–2,422 1,524–2,301
Total mean prevalence rate 3.96/1,000 4.09/1,000 4.05/1,000 3.89/1,000 4.56/1,000 3.86/1,000 
Total mean prevalence rate (age 15–64) 5.89/1,000 6.12/1,000 6.07/1,000 5.80/1,000 6.75/1,000 5.68/1,000
2,070
2,4702,450
2,100
2,530
2,350
1,912
1,264
1,618
1,580
2,057
1,440
1,000
1,500
2,000
2,500
3,000
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
CR2 CR3 (1) CR3 (2) CR4 
M1 M2 M3 M4
MtP Zelterman MtP Chao P(IDU/PDU) M(IDU/HIV)
Mean PDU prevalence Mean IDU prevalence
 Fig. 1. Absolute prevalence estimates of 
PDU and IDU, Luxembourg, 1997–2009 
 [1] . CR2/CR3/CR4 = Capture-recapture 
methods on two, three and four sources. 
M1 = Multiplier method: police and drug-
related deaths registers; M2 = multiplier 
method: number of drug law offenders/
law enforcement contact rate of drug of-
fenders; M3 = multiplier method: num-
ber of fatal overdose cases/drug-related 
mortality rate; M4 = extrapolation from 
treatment data. P(IDU/PDU) = Multi-
plier method: PDU estimates/IDU rates; 
M(IDU/HIV) = multiplier method: num-
ber of HIV-infected IDU/rate of HIV in-
fections among IDU. 
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population. The applicability of the tPm relies on the 
same assumptions as CR models, although the indepen-
dence condition is specific as it assumes that an individ-
ual does not show a behavioral response to being indexed 
at least once. The particularity of the tPm model applied 
in this study lies in the fact that frequency data were pro-
vided by the RELIS database, indexing all national drug-
related contacts with both drug demand or drug supply 
reduction institutions. All sources included in RELIS, 
and previously described, have thus been aggregated into 
a single national and highly representative dataset on 
drug-related institutional contacts.
 Available data also allowed applying a series of multi-
plier methods. The ‘first offender – mortality’ method 
(M1) builds upon the number of first drug law offenders 
(for drug use) during a time window equal to the average 
duration of dependence of national problem drug users 
(A), the number of acute drug deaths during the same 
period (B) and the respective number of acute drug deaths 
having been registered as problem drug users previously 
(C) to provide the total number of problem drug users
(T) = A  ! B/C. The average duration of drug dependence 
has been calculated for each study year on the basis of 
national RELIS data, which reduced the bias that may re-
sult from the application of international literature-based 
dependence duration estimates. Moreover, M1 has been 
applied by including all drug-related deaths cases (direct 
and indirect 2 ) and results were similar to the ones ob-
tained by using acute cases only. As can be seen in  table 1 , 
both estimates have been used as upper and lower bounds 
of estimates calculated by applying M1.
 Due to the representativeness of collected data, de-
scribed precautions to reduce potential bias and the con-
sistency of estimates with results provided by other esti-
mation methods, it can be assumed that the described 
method (M1) is a valuable tool to estimate PDU preva-
lence in Luxembourg. The fact that dependence duration 
can be accurately determined generally via both monitor-
ing and survey data, and that annual variations in the 
number of reported drug offenders and drug-related 
deaths cases have less impact on a given year estimation 
since both represent multi-annual sums in the final equa-
tion, makes this method, as applied, a presumably robust 
and generally recommendable instrument to estimate 
drug misuse prevalence.
 The second applied multiplier method (M2) also relies 
on police data as it estimates the total PDU prevalence by 
dividing the number of registered problem drug users in 
a given year by the proportion of problem drug users hav-
ing reported previous contact with law enforcement. 
Contact with law enforcement is a standard item of the 
national RELIS data protocol and thus allows calculating 
contact rates on a yearly basis and applying them selec-
tively for each serial estimate. However, this method is 
sensitive to the yearly number of registered offenders that 
may differ greatly according to law enforcement activity 
and changes in supply reduction strategies.
 Likewise, the mortality multiplier method (M3), 
though one of the simplest ways to estimate the preva-
lence of drug misuse, is highly sensitive to variations in 
drug-related mortality rates (e.g. HIV/AIDS epidemics, 
high purity or contamination of street drugs). This is 
even more so when the absolute yearly number of drug-
related deaths is relatively small as is the case in Luxem-
bourg. Even slight changes in mortality, not necessarily 
due to a change in the size of the population at risk, may 
have a significant bias impact on estimation results. For 
that reason, and the fact that no national mortality rates 
were available after 1999, this specific method could not 
be applied on a serial basis.
 The last multiplier method (M4) also relies on a bench-
mark (problem drug users in treatment during a given 
year), available at the national level and a multiplier (in-
treatment rate of problem drug users). As the latter has 
not been estimated by any national study since 1997, the 
referred method could not be applied in following years.
 IDU prevalence estimates have been calculated using 
two methods. The P(IDU/PDU) method is straightfor-
ward but its outcome should be considered with caution 
since it relies on two further estimates that are: the esti-
mated number of problem drug users and the proportion 
of injecting drug users in the national PDU population. 
 The M(IDU/HIV) method is obviously more sophisti-
cated and demanding in terms of data input, but its ac-
curacy largely depends on the proportion of HIV-infect-
ed injecting drug users not (yet) diagnosed and the reli-
ability of provided HIV rates in injecting drug users (e.g. 
self-reported or serology-based data). In countries such 
as Luxembourg, where the HIV epidemic in drug users is 
small, even slight changes in the denominator have great 
impact on the estimation result (e.g. a change in the HIV 
infection rate in problem drug users from 2 to 4% will 
result in an estimation decreased by 100%). Moreover, the 
numerator varies according to the impact of new treat-
ment options on the mortality of HIV-infected problem 
 2   Indirect drug-related deaths include known problem drug users who 
died from accidents under the influence of illicit drugs, suicide, drug-re-
lated infectious diseases or consequences of long-term abuse. Aggregated 
data were provided by the police. 
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drug users for instance. Especially in a longitudinal per-
spective, it is crucial that the epidemic remains structur-
ally more or less stable.
 The fact that, in contrast to previous years, the 2007 
and 2009 upper bound estimates, obtained via M(IDU/
HIV), appear to be consistently higher than the P(IDU/
PDU)-based estimation, may stem from the fact that from 
2004 onwards the absolute yearly number of HIV-infected 
persons (which sum is multiplied by the proportion of 
HIV-seropositive persons infected via IDU to obtain a 
proxy for the total number of HIV-infected injecting drug 
users) has been increasing, whereas the proportion of in-
jecting drug users within the HIV-infected population 
has been showing a decreasing trend, partially due to well-
documented  [35] improvements in national harm reduc-
tion offers. Hence, having advanced knowledge of the na-
tional HIV/AIDS epidemic is of utmost importance when 
applying the referred method, especially when small fig-
ures are at stake. These observations also underline the 
need to confront obtained single estimations to results 
from other methods and indirect indicators. 
 A national drug use surveillance system, based on dif-
ferent (DR and SR) sources and settings, referred to as 
‘institutional contact indicator’ in the present paper, and 
able to exclude multiple counts, appears to be a valuable 
instrument to estimate PDU and IDU prevalence and to 
consolidate these by a multi-method approach. National 
PDU estimation based on a single method should be 
avoided as the present study showed that for different 
years all applied methods may provide upper and lower 
bound estimates.
 The framework of a national drug use surveillance 
system, based upon standardized and time-persistent 
data collection routines may reduce bias produced by ex-
ternal factors and cross-sectional data for instance – es-
pecially in the context of serial estimations and trends 
surveillance. The application of CR methods is feasible 
and particularly indicated if these surveillance systems 
build upon case-exhaustive sources. Selected multiplier 
methods may be applied via surveillance data if a series 
of pertinent items are included in the routine protocol 
(i.a. law enforcement contacts, HIV status, duration of 
dependence). Most multiplier methods, however, need 
additional data from other sources (e.g. mortality rate, 
in-treatment rate, proportion of HIV-infected problem 
drug users), which may impede their application. 
 This said, IDU and PDU prevalence estimates should 
be primary based on ‘hard’ data and methodologies least 
relying on specific rates, multipliers or preliminary esti-
mates. Capture-recapture methods, tPms, applied on the 
national PDU population showing institutional contact, 
and the M1 multiplier method, based on longitudinal 
data, showed to be applicable and most reliable in the con-
text of PDU prevalence estimations. As a matter of fact, 
the latter methods seem to provide best input for con-
solidated PDU prevalence estimates but only to the extent 
that external and structural factors, not resulting from an 
actual increase of the population at risk (i.e. changes in 
treatment options or access, HIV outbreak, increased 
mortality due to quality variations in street drugs, chang-
es in data quality), can be assumed to be stable. 
 Sound knowledge of the national drugs problem and 
its correlates is crucial when it comes to take appropriate 
decisions on the accuracy of a given prevalence estima-
tion method and its results. Routine and serial applica-
tion of a selected battery of estimation methods can be a 
valuable tool for drug misuse surveillance. If the choice 
of various methods to be best applied in a given national 
context largely depends on the availability, quality and 
consistency of required data, the methodological issues 
addressed in the present paper may serve the final deci-
sion making.
 Further research should also investigate more dynam-
ic ways to describe PDU and integrate recent findings on 
entry and cessation rates applied to hard drug use  [36] as 
well as the possible associations between indirect trend 
indicators (e.g. drug-related mortality, seizures, service 
usage, treatment demand) and the prevalence of drug 
misuse in a longitudinal perspective in order to fine-tune, 
complement and further validate nationally applied prev-
alence estimations of drug misuse and thus contribute to 
enhance evidence based drug policy planning.
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